CIP
EGRX

Convergence Investment Partners’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Convergence Investment Partners’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-2,699
Closed -$153K – 326
2019
Q3 		$153K Sell
2,699
-1,883
-41% -$106K 0.04% 249
2019
Q2 		$255K Buy
+4,582
New +$239K 0.06% 215
2017
Q3 		– Sell
-14,962
Closed -$1.18M – 406
2017
Q2 		$1.18M Buy
14,962
+7,980
+114% +$653K 0.17% 224
2017
Q1 		$579K Buy
+6,982
New +$519K 0.08% 293

Other funds holding EGRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HEC
Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Convergence Investment Partners's EGRX Position: Q4 2019 in Review

Convergence Investment Partners sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2019, closing a stake of 2,699 shares — an estimated $153K sold.

Convergence Investment Partners first reported a position in EGRX in Q1 2017 and held it in 4 quarters. The position peaked at $1.18M in Q2 2017. 176 funds tracked by Wall St. Rank hold EGRX as of Q4 2019.

  • Convergence Investment Partners reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2019 after selling out during the quarter.
  • Convergence Investment Partners sold 2,699 Eagle Pharmaceuticals, Inc. shares in Q4 2019, an estimated $153K.
  • Convergence Investment Partners first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2017 and held it in 4 quarters.
  • Convergence Investment Partners's Eagle Pharmaceuticals, Inc. position peaked at $1.18M in Q2 2017.
  • 176 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2019.

Based on Convergence Investment Partners's 13F filing for Q4 2019, filed 22 Jan 2020.